🇺🇸 FDA
Pipeline program

Placebo to ARGX-117 IV, ARGX-117, ARGX-117

ARGX-117-2003

Phase 2 small_molecule active

Quick answer

Placebo to ARGX-117 IV, ARGX-117, ARGX-117 for Multifocal Motor Neuropathy is a Phase 2 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
Argenx
Indication
Multifocal Motor Neuropathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials